BrainStorm Cell Therapeutics Provides Update On FDA Advisory Committee Meeting To Review NurOwn For The Treatment Of ALS
Portfolio Pulse from Benzinga Newsdesk
BrainStorm Cell Therapeutics has provided an update on the FDA Advisory Committee meeting to review NurOwn, a treatment for ALS. The outcome of the meeting could have significant implications for the company's future.
September 28, 2023 | 6:43 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The FDA Advisory Committee's review of BrainStorm's ALS treatment NurOwn could significantly impact the company's stock. A positive outcome could boost the stock, while a negative one could lead to a decline.
The FDA's review of NurOwn is a significant event for BrainStorm. If the FDA views the treatment favorably, it could lead to approval and a potential increase in the company's stock. Conversely, if the FDA has concerns or rejects the treatment, it could negatively impact the stock.
CONFIDENCE 80
IMPORTANCE 100
RELEVANCE 100